U.S. Markets closed

GlaxoSmithKline plc (GSK)


NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
42.76+0.35 (+0.81%)
At close: 3:59PM EDT

42.77 0.01 (0.01%)
After hours: 4:02PM EDT

People also watch
AZNNVSSNYLLYBMY
Full screen
Previous Close42.42
Open42.68
Bid42.76 x 3300
Ask42.77 x 1900
Day's Range42.67 - 42.94
52 Week Range37.20 - 45.58
Volume2,887,186
Avg. Volume2,791,725
Market Cap101.32B
Beta1.07
PE Ratio (TTM)48.16
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.95 (4.60%)
Ex-Dividend Date2017-05-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals56 minutes ago

    Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million

    Gaithersburg-based Emergent BioSolutions has been on a bit of a buying spree lately. On Wednesday, the company announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal came less than a week after Emergent (EBS) announced it would buy French pharmaceutical giant Sanofi's smallpox vaccine business in an all-cash deal worth up to $125 million.

  • 17 Non-Tech Firms Making Big Bets On Artificial Intelligence
    Investor's Business Daily1 hour ago

    17 Non-Tech Firms Making Big Bets On Artificial Intelligence

    Loup Ventures has compiled a portfolio of 17 publicly traded non-tech companies that are making investments in artificial intelligence to improve their businesses.

  • What Lies in Store for Glaxo (GSK) this Earnings Season?
    Zacks5 hours ago

    What Lies in Store for Glaxo (GSK) this Earnings Season?

    The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.